ADOCIA Presentations at ADA & IPITA Scientific Conferences Highlight Scalability and Good Translation of AdoShell from Human Islets to Stem Cell-Derived Islets

Regulatory News:

Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity (the “Company”), today announced the presentation of the latest preclinical data from its innovative AdoShell technology platform at ADA & IPITA Scientific Conferences Highlight Scalability and Good Translation of AdoShell from Human Islets to Stem Cell-Derived Islets.

AdoShell is designed to implant human pancreatic islets from deceased donors or stem cell-derived islets cell to cure type 1 diabetes without immunosuppression.

Adocia preclinical data presented at the International Pancreas and Islet Transplant Association (IPITA) 2025 World Congress, held in Pisa, Italy, June 15-18, 2025, was titled “AdoShell, a non-fibrotic encapsulation system for human islet transplantation without immunosuppression”. After implanting AdoShell containing human islets in mice, C-peptide secretion increased during the first two weeks to reach a therapeutic dose (707±218 pM) that was maintained in 100% of mice until explantation after more than 2 months. Moreover, AdoShell Human Islets was shown to regulate mice glycemia to human levels. In vitro, explants showed a maintained viability and glucose-responsive insulin secretion. This presentation also highlights that AdoShell has been successfully scaled-up to embark the human dose of islets for a first clinical application.

The Adocia presentation at the American Diabetes Association’s (ADA) 85^th Scientific Sessions, held in Chicago, USA, June 20-23, 2025, titled “AdoShell, a non-fibrotic encapsulation system enables stem cell-derived islets in vivo maturation for T1DM treatment”, focused on the application of AdoShell to stem cell-derived islets (SCDI). Encapsulation of SCDI in AdoShell maintained viability, proliferation state and secretion of insulin similar to non-encapsulated SCDI. AdoShell permits the maturation of immature SCDI both in vitro and in vivo. Finally, AdoShell enables long-term function and efficacy of SCDI in mice for at least 24 weeks.

“As seen at IPITA and ADA, the field of cell therapy to cure type 1 diabetes is very active, with an emphasis on promising results achieved with stem cell-derived islets in several clinical centers. AdoShell provides solutions to important remaining limitations: containment of these cells allowing their retrievability and removal of lifelong immunosuppressive treatment. With these latest results, we believe that AdoShell could unlock the potential of stem cell-derived islets to treat a larger population safely and effectively.” commented Dr. Rosy Eloy, Chief Medical Officer of Adocia.